Business Wire
09 Jul 2026, 06:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
The Phase 3 CARDIO-TTRansform trial for eplontersen in patients with ATTR-CM failed to meet its primary efficacy endpoint of cardiovascular mortality and recurrent CV clinical events. — Failure of a primary endpoint in a Phase 3 trial significantly reduces the likelihood of regulatory approval and future revenue streams for the drug candidate.
-0.90Which stocks this story touches
The Phase 3 trial for eplontersen failed to meet its primary efficacy endpoint.
As a partner in the trial, the failure of the primary efficacy endpoint is a negative development.
Continue reading
6 related stories
Top 2 movers · tap to explore
[mutual] Ionis Pharmaceuticals and AstraZeneca are partners in the Phase 3 trial for eplontersen.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Proactive Investors
1h ago
